Effect of YM598, a selective endothelin ETA receptor antagonist, on endothelin-1-induced bone formation

European Journal of Pharmacology

Volumn 543, Issue 1-3, 2006, Pages 14-20

  Someya, Akiyoshi ^a   Yuyama, Hironori ^a   Fujimori, Akira ^a   Ukai, Masashi ^a   Fukushima, Shinji ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Bone formation; Endothelin; Selective ETA receptor antagonist

Indexed keywords

ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN 2; CALCIUM ION; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR ANTAGONIST; POTASSIUM N [6 METHOXY 5 (2 METHOXYPHENOXY) 2 (PYRIMIDIN 2 YL)PYRIMIDIN 4 YL] 2 PHENYLENTHENE SULFONAMIDATE; UNCLASSIFIED DRUG; YM 598;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE TISSUE; CALCIUM CELL LEVEL; CELL COUNT; CELL GROWTH; CELL LINE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG ACTIVITY; DRUG EFFECT; DRUG SELECTIVITY; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RAT; THORAX;

ALKALINE PHOSPHATASE; ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEINS; CALCIUM; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG IMPLANTS; ENDOTHELIN-1; MALE; MICE; OSSIFICATION, HETEROTOPIC; OSTEOBLASTS; OSTEOGENESIS; PYRIMIDINES; RATS; RATS, LONG-EVANS; RECEPTOR, ENDOTHELIN A; RECOMBINANT PROTEINS; SULFONAMIDES; TRANSFORMING GROWTH FACTOR BETA;

EID: 33746210023     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.035     Document Type: Article

References (34)

1. Arai H., Hori S., Aramori I., Ohkubo M., and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348 (1990) 730-732
2. Benigni A., Zoja C., Corna D., Orisio S., Facchinetti D., Benatti L., and Remuzzi G. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am. J. Kidney Dis. 27 (1996) 416-423
3. Chen S.J., Chen Y.F., Meng Q.C., Durand J., Dicarlo V.S., and Oparil S. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol. 79 (1995) 2122-2131
4. Erlebacher A., Filvaroff E.H., Gitelman S.E., and Derynck R. Toward a molecular understanding of skeletal development. Cell 80 (1995) 371-378
5. A receptor antagonist, ameliorates the progression of cardiopulmonary changes and both side heart failure in rats with cor pulmonale and myocardial infarction. J. Cardiovasc. Pharmacol. 44 (2004) S64-S67
6. B receptor antagonist ameliorates proteinuria and glomerular lesion in rats with proliferative nephritis. Kidney Int. 50 (1996) 962-972
7. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260 (1985) 3440-3450
8. Inoue A., Yanagisawa M., Kimura S., Kasuya Y., Miyauchi T., Goto K., and Masaki T. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 2863-2867
9. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with Folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
10. Lowry O.H., Roberts N.R., Wu M.L., Hixon W.S., and Crawford E.J. The quantitative histochemistry of brain: II. Enzyme measurements. J. Biol. Chem. 207 (1954) 19-37
11. Miyauchi T., Yorikane R., Sakai S., Sakurai T., Okada M., Nishikibe M., Yano M., Yamaguchi I., Sugishita Y., and Goto K. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alteration in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. 73 (1993) 887-897
12. Miyauchi T., Fujimori A., Maeda S., Iemitsu M., Sakai S., Shikama H., Tanabe T., Matsuda M., Goto K., and Yamaguchi I. Chronic administration of an endothelin-A receptor antagonist improves exercise capacity in rats with myocardial infarction-induced congestive heart failure. J. Cardiovasc. Pharmacol. 44 (2004) S64-S67
13. Mohammad K.S., and Guise T.A. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin. Orthop. Relat. Res. 415S (2003) S67-S74
14. Nelson J.B., Hedican S.P., George D.J., Reddi A.H., Piantadosi S., Eisenberger M.A., and Simons J.W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1 (1995) 944-949
15. Nelson J.B., Chan-Tack K., Hedican S.P., Magnuson S.R., Opgenorth T.J., Bova G.S., and Simons J.W. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 56 (1996) 663-668
16. Nelson J.B., Nguyen S.H., Wu-Wong J.R., Opgenorth T.J., Dixon D.B., Chung L.W.K., and Inoue N. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 53 (1999) 1063-1069
17. Nijweide P.J., Burger E.H., and Feyen J.H. Cells of bone: proliferation, differentiation, and hormonal regulation. Physiol. Rev. 66 (1986) 855-886
18. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., and Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384 (1996) 353-355
19. Sakurai T., Yanagisawa M., Takuwa Y., Miyazaki H., Kimura S., Goto K., and Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of endothelin receptor. Nature 348 (1990) 732-735
20. Scher H.I., and Chung L.W.K. Bone metastases: improving the therapeutic index. Semin. Oncol. 21 (1996) 630-656
21. Schvartz I., Ittoop O., Davidai G., and Hazum E. Endothelin rapidly stimulates tyrosine phosphorylation in osteoblast-like cells. Peptides 13 (1992) 159-163
22. A receptor antagonist, against diabetic nephropathy in OLETF rats. Eur. J. Pharmacol. 450 (2002) 183-189
23. A receptor mediates the signaling of endothelin-1 in osteoblast-like cells. Bone 21 (1997) 143-146
24. 2 receptor antagonist. Naunyn-Schmiedeberg's Ach. Pharmacol. 357 (1998) 63-69
25. 2+ from extra- and intracellular pools in osteoblastic cells. Am. J. Physiol. 257 (1989) E797-E803
26. Takuwa Y., Masaki T., and Yamashita K. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. Biochem. Biophys. Res. Commun. 170 (1990) 998-1005
27. Williams D.L., Jones K.L., Pettibone D.J., Lis E.V., and Clineschmidt B.V. Sarafotoxin S6c: an agonist which distinguishes between endothelin receptor subtypes. Biochem. Biophys. Res. Commun. 175 (1991) 556-561
28. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., and Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332 (1988) 411-415
29. Yin J.J., Mohammad K.S., Kakonen S.M., Harris S., Wu-Wong J.R., Wessale J.L., Padley R.J., Garrett I.R., Chirgwin J.M., and Guise T.A. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10954-10959
30. Yokota S., Sonohara S., Yoshida M., Murai M., Shimokawa S., Fujimoto R., Fukushima S., Kokubo S., Nozaki K., Takahashi K., Uchida T., Yokohama S., and Sonobe T. A new recombinant human bone morphogenetic protein-2 carrier for bone regeneration. Int. J. Pharm. 223 (2001) 69-79
31. A receptor antagonist. Eur. J. Pharmacol. 478 (2003) 61-71
32. A receptor antagonist. Eur. J. Pharmacol. 498 (2004) 171-177
33. Yuyama H., Koakutsu A., Fujiyasu N., Fujimori A., Sato S., Shibasaki K., Tanaka S., Sudoh K., Sasamata M., and Miyata K. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J. Cardiovasc. Pharmacol. 44 (2004) S479-S482
34. A receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur. J. Pharmacol. 492 (2004) 177-182